April 11, 2007
Skinvisible® Signs License Agreement for Leading Topical Pain Reliever
STOPAIN® to use Invisicare® to enhance its product line
LAS VEGAS, April 11, 2007 - Skinvisible, Inc. (OTC Bulletin Board: SKVI / Website: www.skinvisible.com) is pleased to announce it has signed an agreement to license a new topical analgesic formula with Invisicare®, its patented polymer delivery system, to DRJ Group Inc., makers of STOPAIN®.
STOPAIN, a leading over-the-counter topical pain reliever in the $250 million topical analgesic market, will be extending its product line with a new cream formulation which incorporates Invisicare as its delivery system. The addition of Invisicare will keep this product on the skin for an extended period of time; four hours or more, providing on-going relief to people suffering from muscle stiffness, arthritis or muscle strains.
"We are very pleased with this partnership with Skinvisible as their delivery system brings added value to our product and ultimately to our customers that use STOPAIN." said Mr. Robert Miller, President and CEO of DRJ Group Inc. "By including Invisicare, we are offering our customers a product that is different from anything else currently on the market. We expect this advantage to be well received by both the trade and the customer."
"This licensing agreement with DRJ Group is a notable step for Skinvisible as our brand Invisicare will now have nation-wide exposure to consumers in 25,000 pharmacies." said Mr. Terry Howlett, President and CEO of Skinvisible. "We look forward to working closely with the STOPAIN group to find more opportunities to incorporate our technology with their pain relief products."
Skinvisible's business model is focused on licensing its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. In addition to the polymer revenue, Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent.
About Invisicare®
Skinvisible has patented its technology and trademarked its polymer delivery system, Invisicare. Invisicare is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. See:
www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Headquartered in Las Vegas, Nevada, Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its technology and formulated products to manufacturers of Rx and OTC skincare products. See
www.skinvisible.com
About DRJ Group Inc.
DRJ, founded in 1991, markets its STOPAIN branded pain relievers in over 25,000 independent pharmacies and national chain drug stores including Walgreens, CVS, RiteAid, Eckerds, Brooks and Longs Drug.
Forward-Looking Statements
This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10K for the year ending December 31, 2006.)
BACK TO: News Index
Top
